Roman-Ulrich Müller

Roman-Ulrich Müller

@muellerrom.bsky.social

passionate for translational research...kidney disease and beyond...

108 followers21 following82 posts

Roman-Ulrich Müller reposted

Universität zu Köln
@unicologne.bsky.social

💻️💉 A research team led by Professor Dr Roman-Ulrich Müller has developed the digital platform MEDA-PKD. It links clinical follow-up data, laboratory results, imaging, information on medication and quality of life, initial molecular data on new biomarkers and other data. ➡️ uni.koeln/9YM53 #UniCologne

uni.koelnNew MEDA-PKD platform provides real-time data to help research and treat polycystic kidney diseaseResearchers at the University of Cologne and Heinrich Heine University Düsseldorf (HHU) have developed the digital platform MEDA-PKD. Using the example of polycystic kidney disease, this initiative br...

Roman-Ulrich Müller reposted

Universität zu Köln
@unicologne.bsky.social

💻️ 💉 Ein Forschungsteam unter Leitung von Prof. Dr. Roman-Ulrich Müller hat die digitale Plattform MEDA-PKD entwickelt. Sie verknüpft u.a. klinische Verlaufsdaten, Laborwerte, Bildgebung, Angaben zu Medikamenten und Lebensqualität sowie erste molekulare Daten zu neuen Biomarkern. ➡️ uni.koeln/KFUW2

uni.koelnNeue Plattform MEDA-PKD liefert Echtzeitdaten zur Erforschung und Behandlung von ZystennierenForschende der Universität zu Köln und der Heinrich-Heine-Universität Düsseldorf (HHU) haben die digitale Plattform MEDA-PKD entwickelt. Diese vereint erstmals am Beispiel der Zystenniere bislang unst...

Roman-Ulrich Müller reposted

CECAD Cologne
@cecad.bsky.social

🔍@muellerrom.bsky.social and Philipp Antczak, among others, have developed the digital platform MEDA-PKD using polycystic kidney disease (#PKD) as a case study. 📊Data from clinical care and research are continuously consolidated and can be analyzed in near real time. sohub.io/4rst

View full thread

Roman-Ulrich Müller reposted

PKD International
@pkdinternational.bsky.social

🧵🌍 A new milestone for the STOP-PKD Study. Fundació Puigvert Barcelona has officially become the first active STOP-PKD trial site in Spain. This is an important step forward for the study and for the international effort to advance research in ADPKD.

Roman-Ulrich Müller reposted

PKD International
@pkdinternational.bsky.social

🧵🧪 STOP-PKD study | Five additional trial sites successfully initiated The STOP-PKD study continues to expand its network across Europe, with five additional trial sites now successfully initiated in the Netherlands, Germany and Austria.

Roman-Ulrich Müller reposted

Andreas Beyer Group
@beyerlab.bsky.social

Paper out on single-cell damage scores.📜Quantify the damage of single podocytes or hepatocytes using their transcriptomes to study degenerative diseases. Big congrats to the Beyer-Lab members Tim Padvitski and Paula Unger 🍾🌟🎉 Thanks to all the fantastic collaborators! www.cell.com/cell-genomic...

cell.comCell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomicsPadvitski, Unger Avila, Chen et al. introduce a single-cell transcriptomic framework that quantifies progressive cellular damage across degenerative disease models. Applied to kidney and liver injury,...

Roman-Ulrich Müller reposted

PKD International
@pkdinternational.bsky.social

🧵⏳ 10 days to go | 1st PKD Global Members Meeting In just 10 days, leaders from PKD International member organisations will come together in Leuven, Belgium, for the first PKD Global Members Meeting.

Roman-Ulrich Müller reposted

CRC1678
@crc1678.bsky.social

🚨 Publication Alert 🚨 New study from #CRC1678 members @beyerlab.bsky.social and @muellerrom.bsky.social maps kidney and liver disease using cell‑type‑specific damage scores. PDS/HDS track cell injury and reveal circadian disruption and a MASLD/NASH threshold. 🍾🥳 👉 www.cell.com/cell-genomic...

cell.comCell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomicsPadvitski, Unger Avila, Chen et al. introduce a single-cell transcriptomic framework that quantifies progressive cellular damage across degenerative disease models. Applied to kidney and liver injury,...

Roman-Ulrich Müller reposted

MPI for Biology of Ageing
@mpiage.bsky.social

📢 Publication alert New study from the @antebilab.bsky.social on Verheij syndrome, a rare genetic developmental disorder linked to defects in RNA splicing. www.nature.com/articles/s41...

nature.comVitamin B12 alleviates spliceosomopathy via phospholipid remodeling - Nature CommunicationsThe authors use a Caenorhabditis elegans model of Verheij syndrome, caused by mutations in the splicing factor PUF60, and show that Vitamin B12 can rescue the phenotype.

Roman-Ulrich Müller reposted

PKD International
@pkdinternational.bsky.social

🧵🧪 STOP-PKD study | Four additional trial sites activated The STOP-PKD study continues to expand its recruitment network across Europe, with four additional trial sites now initiated: three in Germany and a second centre in Austria.

Roman-Ulrich Müller
@muellerrom.bsky.social

Wir suchen hoch motivierte Kolleg*innen, die Spaß daran haben unser interdisziplinäres Team zu ergänzen. Eine herausfordernde Position, mit der wir gemeinsam die nächsten Schritte in die Zukunft der Klinik für Nephrologie gehen möchten. Ich freue mich auf die Zusammenarbeit!

Roman-Ulrich Müller
@muellerrom.bsky.social

Interested in working on RNA-biology in human disease? We can offer a PhD student position in a great team. Looking into RNA-modifications as a driver of polycystic kidney disease together with @landthalerm.bsky.social www.jobvector.de/job/phd-stud...

jobvector.dePhD Student*in (m/w/d) | Job in DüsseldorfConducting innovative research in line with the above-mentioned project. Collecting, analyzing, and interpreting data using various OMICs techniques. Conducting in vitro and in vivo experiments. Colla...
Roman-Ulrich Müller
@muellerrom.bsky.social

We’re excited to share our latest publication in npj Aging on the molecular effects of short-term calorie restriction before living kidney donation. Using proteomics, lipidomics, and cytokine profiling, we found that just 7 days of 50% calorie restriction induced molecular signatures linked to: 🧵

Roman-Ulrich Müller
@muellerrom.bsky.social

• reduced insulin/IGF signaling • modulation of inflammatory pathways • enhanced metabolic adaptation • stress resistance mechanisms conserved across species These findings strengthen the translational bridge between longevity research and clinical nephrology/transplantation. 🧵

Roman-Ulrich Müller
@muellerrom.bsky.social

Great collaborative effort — thanks to everyone involved! www.nature.com/articles/s41... #Aging #Longevity #KidneyTransplantation #Nephrology #CalorieRestriction @cecad.bsky.social @uniklinikkoeln.bsky.social @hhu.de

nature.comAn in-depth analysis of the molecular changes induced by short-term calorie restriction before living kidney donation - npj Agingnpj Aging - An in-depth analysis of the molecular changes induced by short-term calorie restriction before living kidney donation
Roman-Ulrich Müller
@muellerrom.bsky.social

I usually think twice before posting preprints. But this time it’s different. MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research. 🧵

View full thread
Roman-Ulrich Müller
@muellerrom.bsky.social

I usually think twice before posting preprints. But this time it’s different. MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research. 🧵

View full thread
Roman-Ulrich Müller
@muellerrom.bsky.social

🔍 Current cohort: • 1,735 ADPKD patients (and growing continuously) • 20,000+ lab measurements • longitudinal tracking of kidney function, imaging, medications & QoL • interactive dashboards for subgroup analyses & patient trajectories

Roman-Ulrich Müller
@muellerrom.bsky.social

One exciting finding: 📉 Real-world analyses showed ~27% slowing of kidney function decline under tolvaptan — remarkably close to pivotal trial data, highlighting the power of real-time therapeutic monitoring.

Roman-Ulrich Müller
@muellerrom.bsky.social

I usually think twice before posting preprints. But this time it’s different. MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research. 🧵

Roman-Ulrich Müller
@muellerrom.bsky.social

I’ve been using the platform myself almost daily since its prefinal version went live last year, and I’m genuinely excited to finally share it with the community. 🚀 Today we present MEDA-PKD: a dynamic, real-time analytics platform for precision care in ADPKD.

Roman-Ulrich Müller
@muellerrom.bsky.social

Instead of static registry snapshots, MEDA-PKD creates a continuously learning ecosystem integrating: • clinical routine data • imaging • laboratory values • patient-reported outcomes • proteomics & omics data —all within one harmonized interactive platform.

Roman-Ulrich Müller
@muellerrom.bsky.social

New publication on hereditary kidney tumors. Our questionnaire-based screening approach (referenced in the German giudeline) has now been validated. A step toward better identification of patients who may benefit from genetic evaluation and personalized care. 📖 academic.oup.com/ckj/advance-...

academic.oup.comHereditary kidney tumor syndromes: structured evaluation of a questionnaire-based approachAbstractBackground. Up to 8% of renal tumors have a monogenic cause, yet hereditary renal cell carcinoma (hRCC) syndromes such as Von Hippel–Lindau (VHL),
Roman-Ulrich Müller
@muellerrom.bsky.social

ADPKD comes with increased risk of aneurysms. This manifestation comes concern, for both patients and MDs. Risk assessment? Screening? Treatment decisions? This ERA Genes&Kidney commentary provides fin-depth guidance based on the @kdigo.org ADPKD guideline. academic.oup.com/ndt/article/...

academic.oup.comKDIGO 2025 Clinical Practice Guideline for ADPKD: a commentary on intracranial aneurysms and other vascular manifestations from the ERA Working Group Genes & KidneyAbstract. The 2025 KDIGO Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease (ADPKD) addresses intracranial aneurysms (ICAs) and o